Sinopharm Group

Corporate brand

China’s centrally administered pharmaceutical and healthcare group spanning drug research, biopharmaceuticals, vaccines, medical devices, distribution, retail, healthcare services and international trade.

Last updated October 9, 2026

Overview

Sinopharm Group, formally China National Pharmaceutical Group Corporation, is one of China's largest state-owned healthcare enterprises. Its activities cover pharmaceutical research and manufacturing, vaccines and biological products, active pharmaceutical ingredients, traditional Chinese medicine, medical devices, pharmaceutical distribution, retail pharmacy, logistics, engineering, and healthcare-related services. The group is commonly known internationally as Sinopharm and should be distinguished from Sinopharm Group Co., Ltd., a publicly traded distribution and healthcare subsidiary of the wider China National Pharmaceutical Group system. The organization developed from China's state pharmaceutical administration and industrial infrastructure. Its position combines commercial operations with a strategic public-health role: the group supplies medicines and medical products to hospitals, pharmacies, public-health institutions, and other customers, while its research and manufacturing units participate in national vaccine and biologics programs. The central government, through the State-owned Assets Supervision and Administration Commission of the State Council, exercises ownership oversight over the parent group. Sinopharm's business is organized through a broad network of manufacturing and distribution companies. Major activities include prescription medicines, over-the-counter products, vaccines, blood products, diagnostic products, chemical ingredients, biological medicines, medical equipment, and healthcare supply-chain services. Its distribution businesses connect domestic and multinational pharmaceutical manufacturers with hospitals and other healthcare providers across China. This gives the group a role not only as a producer but also as a national-scale intermediary in the country's medicine-supply system. The group became especially visible during the COVID-19 pandemic through China National Biotec Group, or CNBG, and its Beijing and Wuhan biological-product institutes. These units developed and manufactured inactivated COVID-19 vaccines that were supplied in China and exported or donated to other countries. The World Health Organization listed the Sinopharm COVID-19 vaccine for emergency use in 2021, supporting its deployment through international procurement and vaccine-sharing programs. The pandemic strengthened Sinopharm's international profile but also led to scrutiny of vaccine efficacy data, transparency, and the broader governance of Chinese vaccine development. Sinopharm's public identity therefore combines industrial scale, state ownership, healthcare infrastructure, and pharmaceutical branding. It is not a single consumer product label: it is a diversified corporate group whose products and services are delivered through numerous subsidiaries and institutional brands. Its current strategic importance lies in securing medicine supplies, expanding innovative and biological medicines, developing vaccines and diagnostics, improving distribution efficiency, and supporting China's broader healthcare and life-sciences objectives. Sinopharm is the common English name of China National Pharmaceutical Group Co., Ltd., one of China’s largest state-owned pharmaceutical and healthcare conglomerates. The company operates as a broad industry platform rather than as a single-product consumer brand. Its activities extend across pharmaceutical research and manufacturing, vaccines and blood products, chemical medicines, traditional Chinese medicine, medical devices, pharmaceutical distribution, retail pharmacies, healthcare services, engineering, exhibitions, investment and international trade. The group was established on November 26, 1998, as a holding company bringing together several national pharmaceutical and medical-supply enterprises, including China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Device Corporation. In 2009, it was merged with China National Biotec Group, substantially strengthening its biotechnology, vaccine and blood-product capabilities. The resulting organization became a centrally administered state-owned enterprise supervised by China’s State-owned Assets Supervision and Administration Commission. Sinopharm’s business model combines industrial manufacturing with commercial circulation. Through subsidiaries such as China National Biotec Group and major pharmaceutical manufacturers, the group produces vaccines, plasma-derived and other biological products, chemical medicines and traditional Chinese medicines. Through Sinopharm Group Co., Ltd., its principal commercial subsidiary, it distributes medicines, medical equipment, consumables and healthcare products to hospitals, community health institutions, pharmacies and other distributors. Sinopharm Holding also operates retail pharmacy networks and supply-chain services. This vertical structure gives the group a role in several stages of the healthcare value chain, from research and production to warehousing, delivery, retail and clinical support. The group’s most internationally recognizable product achievement was the Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV. Developed by the Beijing Institute of Biological Products under China National Biotec Group, the vaccine used an inactivated-virus platform and was designed for storage and distribution at ordinary refrigerated temperatures. Following clinical studies in several countries, the World Health Organization listed the vaccine for emergency use on May 7, 2021, enabling its use through international procurement and COVAX-related channels. Sinopharm also developed a second inactivated COVID-19 vaccine through the Wuhan Institute of Biological Products. Although the COVID-19 vaccines brought the Sinopharm name to global public attention, the group’s underlying business is much broader. Its portfolio includes biological medicines, vaccines for infectious diseases, blood products, modern Chinese medicines, generic and specialty chemical drugs, medical imaging and treatment equipment, laboratory products, hospital supplies and pharmaceutical logistics. The company also works with foreign pharmaceutical, medical-device and healthcare companies to import products into China, localize manufacturing, develop distribution networks and pursue regulatory approvals. Sinopharm has expanded its international role through exports, overseas production collaborations, medical-aid projects, hospital construction and participation in global healthcare programs. In 2026, the group described its international operations as reaching more than 70 countries and regions, with Belt and Road markets serving as an important area for expansion. Its international strategy includes vaccine technology cooperation, local production arrangements, medical-equipment supply and overseas healthcare infrastructure. The group’s ownership structure is complex because many operating businesses are separately incorporated and publicl…

History

China National Pharmaceutical Group Corporation emerged from China's state pharmaceutical administration and industrial system and was established in 1987. It was created to coordinate pharmaceutical manufacturing, research, distribution, and related healthcare activities at a national level. Over time, the organization consolidated a wide range of enterprises involved in chemical medicines, biological products, vaccines, traditional Chinese medicine, medical equipment, pharmaceutical commerce, and logistics. The group operates under the oversight of China's central state-asset administration system. Unlike a focused pharmaceutical company, it functions as a diversified healthcare conglomerate. Its manufacturing companies develop and produce medicines and biological products, while its commercial subsidiaries distribute products to hospitals, pharmacies, public-health agencies, and other healthcare institutions. The group also has engineering, research, import and export, retail, and supply-chain capabilities. This structure has made it an important part of China's national medicine-distribution infrastructure. A major component of the group is China National Biotec Group, generally known as CNBG. CNBG brings together vaccine and biological-product institutes, including major Beijing and Wuhan facilities. These organizations have long worked on human vaccines, blood products, diagnostic reagents, and other biological medicines. Their work includes products for infectious diseases and public-health programs as well as commercial healthcare markets. Sinopharm also developed an important listed-company platform. Sinopharm Group Co., Ltd. was established as a pharmaceutical distribution and healthcare company and later listed in Hong Kong. It is associated with the broader Sinopharm group but is not identical to the parent corporation. Other group companies operate in manufacturing, medical devices, retail pharmacy, and specialized biological-product businesses. The group's corporate architecture consequently includes both wholly controlled state-owned entities and publicly traded subsidiaries. The COVID-19 pandemic brought Sinopharm's vaccine operations to global attention. CNBG units developed inactivated SARS-CoV-2 vaccines, and Chinese regulators authorized their use in late 2020. The vaccines were then supplied domestically and internationally. In May 2021, the World Health Organization granted emergency-use listing to the Sinopharm vaccine, making it eligible for international procurement mechanisms and contributing to vaccination programs in countries across Asia, Africa, Latin America, and the Middle East. Sinopharm's pandemic role included manufacturing, export, donations, and participation in broader diplomatic and public-health efforts. The pandemic period also generated criticism and debate. International observers and researchers sought more detailed clinical-trial information and real-world effectiveness data than was initially available publicly. Questions about evidence transparency and the performance of inactivated vaccines were discussed alongside broader debates about vaccine access, regulatory review, and the role of state-owned pharmaceutical companies. These issues did not end Sinopharm's international deployment, but they shaped the scrutiny attached to its vaccines. In its present form, Sinopharm remains a broad healthcare platform rather than a single-product brand. Its strategic priorities include maintaining medicine and vaccine supply, upgrading manufacturing, expanding biological and innovative medicines, developing diagnostics and medical devices, and improving national distribution networks. The group continues to serve domestic institutional healthcare demand while pursuing selected international sales, partnerships, and public-health projects. Sinopharm’s institutional history reflects the consolidation of China’s national pharmaceutical, medical-device and healthcare-supply assets into a centrally coordinated corporate group. The organization was formally created on November 26, 1998, under the name China National Pharmaceutical Group Corporation. Rather than being founded by a single entrepreneur, it was assembled as a holding company for several existing state-owned entities: China National Pharmaceutical Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Device Corporation. The creation of the group gave the Chinese government a national platform for coordinating pharmaceutical manufacturing, foreign trade, medical-device production and the distribution of essential healthcare products. During its early development, Sinopharm combined industrial assets with commercial and trading operations. Its companies manufactured medicines and medical products while also importing, exporting and distributing products for domestic and overseas suppliers. This structure allowed the group to participate in both production and circulation, an important capability in China’s large and geographically dispersed healthcare system. Over time, the group expanded its activities into chemical pharmaceuticals, traditional Chinese medicine, medical devices, healthcare services, pharmaceutical logistics and retail pharmacy. A decisive turning point came in 2009, when Sinopharm was merged with China National Biotec Group. CNBG brought together important biological-product capabilities, including vaccine and blood-product research and production. The merger increased Sinopharm’s role in public-health manufacturing and created the institutional base for later vaccine development. It also linked the group more closely to China’s national immunization and biological-products infrastructure. Another major phase involved the development of Sinopharm’s commercial platform. Sinopharm Group Co., Ltd., established in Shanghai in January 2003, became the group’s principal pharmaceutical and medical-device distribution arm. Its shares were listed on the Hong Kong Stock Exchange in September 2009 under stock code 01099. Sinopharm Group developed a nationwide network serving hospitals, primary-care institutions, pharmacies, distributors and other healthcare customers. Its subsidiaries included China National Medicines Corporation and China National Accord Medicines, both of which became separately listed companies. The parent Sinopharm group retained indirect influence through holding companies and investment structures, while the listed subsidiaries operated as distinct legal entities. The group’s industrial portfolio also broadened through the integration of major manufacturers and research organizations. Shanghai Shyndec Pharmaceutical, for example, became part of Sinopharm in 2010 and later participated in restructuring and integration of the chemical-pharmaceutical sector. Other significant businesses included China National Biotec Group, the Beijing and Wuhan institutes of biological products, Taiji Group and various pharmaceutical, medical-device and healthcare-service subsidiaries. Through these entities, Sinopharm developed a portfolio covering vaccines, blood products, chemical medicines, traditional Chinese medicines and medical equipment. Sinopharm’s public profile changed dramatically during the COVID-19 pandemic. Its Beijing Institute of Biological Products and Wuhan Institute of Biological Products developed inactivated-virus vaccine candidates in 2020. The Beijing product, generally known as BBIBP-CorV or the Sinopharm BIBP vaccine, entered international clinical studies and was used in vaccination programs in multiple regions. The product’s conventional refrigerated storage requirements made it operationally attractive for countries without extensive ultra-cold-chain infrastructure. On May 7, 2021, the World Health Organization listed the BIBP vaccine for emergency use. This made it eligible for international procurement through COVAX-related channels and helped establish Sinopharm as one of the most visible Chinese healthcare brands worldwide. The pandemic also accelerated the group’s investment in vaccine capacity, international partnerships and technology cooperation. Sinopharm worked with governments, manufacturers and healthcare companies in countries including the United Arab Emirates, Egypt, Morocco, Serbia, Bangladesh and others on clinical research, manufacturing, filling, distribution and regulatory access. The group later emphasized broader internationalization beyond COVID-19 vaccines, including overseas production arrangements for vaccines, exports of medicines and traditional Chinese medicines, medical-equipment projects and hospital construction. Sinopharm’s history also includes a significant quality-control controversy. In 2017, Chinese regulatory sampling identified a DPT vaccine batch made by the Wuhan Institute of Biological Products that failed potency requirements. Regulators stated that 400,520 doses were affected and attributed the problem primarily to a temporary filling-equipment malfunction that caused uneven distribution of the vaccine suspension. Unused doses were recalled and destroyed, the subsidiary was fined and the company was required to improve equipment maintenance, filling procedures, staff training and quality controls. The episode became part of the wider 2018 Chinese vaccine-safety crisis and placed renewed attention on manufacturing oversight and public confidence. In the 2020s, Sinopharm pursued a dual strategy: reinforce its core role in pharmaceutical manufacturing and distribution while moving toward digital, international and service-oriented healthcare operations. It expanded collaboration with global companies such as Pfizer, Elekta, Medtronic, Abbott, Siemens Healthineers and other international suppliers. It also increased participation in the China International Import Expo, used procurement partnerships to bring foreign medical technologies into China and promoted traditional Chinese medicine products in overseas markets. By 2026, Sinopharm presented itself as a comprehensive healthcare group with one of China’s broadest pharmaceutical industry chains. Its activities included biopharmaceuticals, vaccines, blood products, chemical medicines, traditional Chinese medicine, medical equipment, pharmaceutical distribution, retail pharmacies, healthcare services, engineering, investment and international business. Its continuing significance derives from the combination of state ownership, industrial scale, distribution reach, public-health responsibilities and the ability to connect domestic healthcare demand with international suppliers and markets.

2026
International business described as reaching more than 70 countries and regions
[13]Sinopharm international expansion reporten.sinopharm.com
Sinopharm reported expanding exports, vaccine localization, overseas healthcare projects and Belt and Road cooperation across more than 70 countries and regions.
2025
Tongtian Oral Liquid authorized in Canada
[14]Sinopharm Tongtian Oral Liquid authorization in Canadaen.sinopharm.com
A traditional Chinese medicine product from Sinopharm’s Taiji Group received Canadian authorization as a Natural Health Product.
2024
University of Macau strategic cooperation
[18]University of Macau strategic cooperationen.sinopharm.com
Sinopharm signed a strategic cooperation framework with the University of Macau covering life-health research and related cooperation.
2023
Pfizer cooperation agreement
[15]Pfizer-Sinopharm strategic cooperation reportfinance.yahoo.com
Pfizer and Sinopharm Group agreed to cooperate on regulatory approval and market access for innovative Pfizer medicines in China.
2021
WHO emergency-use listing for Sinopharm BIBP vaccine
[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
The WHO lists the Sinopharm COVID-19 vaccine for emergency use, enabling its inclusion in international procurement and vaccine-sharing programs.
2020
Chinese authorization of Sinopharm COVID-19 vaccines
[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Inactivated COVID-19 vaccines developed by CNBG units receive Chinese authorization and begin wider domestic deployment.
2020
Sinopharm COVID-19 vaccine candidates enter clinical development
[17]Sinopharm COVID-19 vaccine candidates enter clinical developmenten.wikipedia.org
Sinopharm’s Beijing and Wuhan biological-product institutes advanced inactivated COVID-19 vaccine candidates into clinical trials and international cooperation.
2018
Recall, destruction and regulatory rectification of DPT vaccine
[12]Chinese regulator information on Wuhan DPT vaccinexinhuanet.com
Unused doses were recalled and destroyed; the Wuhan subsidiary was fined and required to improve manufacturing controls and equipment maintenance.
2017
Substandard DPT vaccine identified at Wuhan subsidiary
[12]Chinese regulator information on Wuhan DPT vaccinexinhuanet.com
Regulatory sampling identified an ineffective-potency DPT vaccine batch made by Wuhan Institute of Biological Products.
2010
Shanghai Shyndec becomes part of Sinopharm
[16]Shanghai Shyndec becomes part of Sinopharmen.sinopharm.com
Shanghai Shyndec Pharmaceutical was incorporated into Sinopharm in April 2010 and later participated in chemical-pharmaceutical restructuring.

Showing the 10 most recent.

Products and positioning

A state-owned, nationally scaled Chinese healthcare and pharmaceutical platform combining manufacturing, vaccines and biologics, medical products, pharmaceutical distribution, and healthcare services. A state-backed, vertically integrated pharmaceutical and healthcare group positioned as a national healthcare-supply platform, major Chinese medicine and medical-device distributor, vaccine producer and international healthcare partner.

Inactivated vaccine · 2020
Sinopharm BIBP COVID-19 vaccine
An inactivated SARS-CoV-2 vaccine developed and manufactured by units of China National Biotec Group. It was used in China's domestic vaccination program and supplied internationally. WHO emergency-use listing in 2021 enabled its consideration for international procurement and deployment. An inactivated-virus COVID-19 vaccine developed by Sinopharm’s Beijing Institute of Biological Products under China National Biotec Group. Known as BBIBP-CorV or the BIBP vaccine, it was tested in international Phase III studies and received WHO emergency-use listing on May 7, 2021. Its conventional refrigerated storage requirements supported distribution in countries without extensive ultra-cold-chain infrastructure. A second inactivated-virus COVID-19 vaccine developed by Sinopharm’s Wuhan Institute of Biological Products. The product was developed separately from the Beijing BIBP vaccine and formed part of Sinopharm’s pandemic vaccine portfolio.
Vaccines
Human vaccines
Sinopharm's biological-product businesses develop and manufacture vaccines for infectious diseases and public-health programs. The portfolio is produced through specialized institutes and manufacturing companies rather than through one uniform consumer-facing product line.
Healthcare distribution · 2003
Pharmaceutical distribution services
The group's distribution operations supply prescription medicines, biological products, medical devices, and other healthcare goods to hospitals, pharmacies, clinics, and public-health institutions. This is one of Sinopharm's defining capabilities and is particularly significant in China's institutional healthcare market. Through Sinopharm Group, the company distributes medicines, medical devices, consumables and healthcare products to hospitals, community health institutions, pharmacies and other distributors. The business includes warehousing, delivery, supply-chain management and value-added services.
Biologics
Biological products and blood products
Sinopharm companies manufacture and distribute biological medicines, blood-derived products, diagnostic materials, and related products. These activities are concentrated in specialized biological-product subsidiaries and research institutes.
Medical technology
Medical devices and diagnostics
The group participates in medical-device, diagnostic, laboratory, and healthcare-equipment businesses, complementing its pharmaceutical manufacturing and distribution activities.
Biopharmaceuticals
Vaccines and biological products
Sinopharm’s biological-products portfolio includes preventive vaccines, blood products, immunological products and other biotechnology-based medicines produced through China National Biotec Group and affiliated institutes. These products support national immunization, infectious-disease prevention and broader clinical use.
Pharmaceutical medicines
Chemical pharmaceuticals
The group manufactures and distributes a wide range of chemical medicines, including generic and specialty products. Its chemical-pharmaceutical operations have been supported by industrial restructuring, research institutes, manufacturing subsidiaries and Sinopharm’s large distribution network.
Traditional Chinese medicine
Traditional Chinese medicine portfolio
Sinopharm’s TCM activities include proprietary medicines, oral liquids and herbal preparations produced by subsidiaries such as Taiji Group. Products are marketed in China and, for selected formulations, in international markets including Singapore, Malaysia and Canada.
Medical devices
Medical-device distribution and supply-chain services
Sinopharm distributes diagnostic, surgical, imaging, laboratory, treatment and hospital-support equipment. It also works with international manufacturers to introduce advanced devices and healthcare technologies into the Chinese market.
Retail healthcare
Retail pharmacy and healthcare services
The group’s commercial subsidiaries operate retail pharmacies, professional pharmacy formats, direct-to-patient services, retail clinics and related healthcare platforms. These businesses connect Sinopharm’s wholesale network with consumers and community-based healthcare delivery.

Controversies

2017
Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products
Chinese regulatory sampling found that a DPT vaccine batch produced by Sinopharm’s Wuhan Institute of Biological Products failed potency requirements. Regulators reported that 400,520 doses were affected. The stated cause was a temporary filling-equipment malfunction that made the vaccine suspension uneven. Unused doses were recalled and destroyed, and the subsidiary was fined and required to strengthen equipment maintenance, filling procedures, training and quality controls.
Source
Ineffective DPT vaccine incident (2017)
Source

2025Internationalization of traditional Chinese medicine
Canada · Singapore · Malaysia · Other international markets
Sinopharm promoted selected traditional Chinese medicine formulations through overseas registrations, trade events and local market access initiatives.
Outcome. Tongtian Oral Liquid received Canadian authorization as a Natural Health Product, while other Taiji products had previously obtained market access in Singapore and Malaysia.
Source
2023All for Health, Health for All
China · International markets
Sinopharm has used the “All for Health, Health for All” theme to frame its public-health, pharmaceutical distribution, supply-security, innovation and international cooperation activities.
Outcome. The theme supports the group’s positioning as a national healthcare platform rather than a single-product pharmaceutical manufacturer.
Source
2021International Sinopharm COVID-19 vaccination deployment
China · Asia · Africa · Latin America · Middle East
Following domestic authorization and WHO emergency-use listing, Sinopharm COVID-19 vaccines were supplied through international agreements, donations, and multilateral vaccine-access programs.
Outcome. The campaign expanded the vaccine's international use and made Sinopharm one of the most visible Chinese vaccine suppliers during the pandemic.
Source
2020Global COVID-19 vaccine supply and vaccination cooperation
Asia · Africa · Europe · South America · Middle East
Sinopharm promoted its inactivated COVID-19 vaccines through international clinical trials, government procurement, technology cooperation, local manufacturing discussions and vaccination campaigns. The effort focused particularly on countries where conventional refrigerated distribution was more practical than ultra-cold-chain systems.
Outcome. The BIBP vaccine received WHO emergency-use listing in May 2021 and became one of the Chinese vaccines used in international immunization programs and COVAX-related procurement.
Source
2018China International Import Expo participation
China · International supplier markets
Sinopharm began participating in the China International Import Expo in 2018, using the event to connect Chinese healthcare demand with global pharmaceutical, medical-device, nutrition and health-product suppliers.
Outcome. The expo became an important annual platform for procurement agreements, international partnerships and the introduction of foreign medical technologies into China.
Source

Brand decisions

2024
Expand international procurement and medical-technology partnershipsStrategy
Background
Sinopharm sought to combine its domestic distribution capabilities with international medical technologies and healthcare products.
Action taken
The group used the China International Import Expo and related initiatives to sign procurement agreements and deepen cooperation with global medical-device and healthcare companies.
Aftermath
The strategy reinforced Sinopharm’s position as an importer, distributor, technology partner and healthcare-supply-chain integrator.
Source
2023
Cooperate with Pfizer on innovative medicines in ChinaStrategy
Background
Pfizer sought to broaden access to innovative medicines in China, while Sinopharm possessed extensive regulatory, distribution and commercial infrastructure.
Action taken
Pfizer and Sinopharm Group signed a strategic cooperation agreement covering applications for 12 innovative drugs through 2025.
Aftermath
The agreement illustrated Sinopharm’s role as a local market-access and distribution partner for multinational pharmaceutical companies.
Source
2021
Pursuit of international vaccine supplyStrategy
Background
Global vaccine shortages and unequal access created demand for additional suppliers beyond the first Western-developed vaccines.
Action taken
Sinopharm supplied vaccine doses to overseas markets and participated in international access and procurement arrangements after WHO emergency-use listing.
Aftermath
The group increased its international healthcare visibility and strengthened its role in China's outward-facing public-health and pharmaceutical activities.
Source
2020
Emergency development and deployment of an inactivated COVID-19 vaccineProduct launch
Background
The COVID-19 pandemic created urgent demand for vaccines and expanded the strategic importance of domestic vaccine manufacturing.
Action taken
CNBG units developed, manufactured, and supplied an inactivated SARS-CoV-2 vaccine for domestic use, followed by international distribution.
Aftermath
The vaccine became a major international product and later received WHO emergency-use listing, while its evidence base and transparency were subject to international discussion.
Source
2020
Develop and commercialize inactivated COVID-19 vaccinesProduct launch
Background
The COVID-19 pandemic created urgent demand for vaccines that could be manufactured at scale and distributed through conventional refrigerated supply chains.
Action taken
Sinopharm’s Beijing and Wuhan biological-product institutes advanced separate inactivated-virus vaccine candidates through clinical development, regulatory review and international partnerships.
Aftermath
The BIBP vaccine received WHO emergency-use listing in May 2021 and became a major product in Sinopharm’s international profile.
Source
2009
Merge with China National Biotec GroupM&A
Background
Sinopharm sought to strengthen its biological-products and public-health manufacturing capabilities.
Action taken
China National Biotec Group was merged into Sinopharm.
Aftermath
The merger expanded the group’s vaccine, blood-product and biotechnology platform and supported later COVID-19 vaccine development.
Source
1998
Create a national pharmaceutical holding platformStrategy
Background
China had multiple large state-owned pharmaceutical, foreign-trade and medical-device enterprises operating across related parts of the healthcare system.
Action taken
The government established China National Pharmaceutical Group Corporation as a holding company consolidating four major predecessor organizations.
Aftermath
The structure gave Sinopharm a broad base in manufacturing, foreign trade, medical devices and pharmaceutical supply, and later enabled further sector consolidation.
Source

Recent events

2026
Sinopharm chairman attends UK-China Business Council meeting[21]国药集团董事长出席英中贸易协会会议en.sinopharm.com
Leadership change · Other
Chairman Bai Zhongquan represented Sinopharm at a UK-China business meeting and highlighted the group’s broad pharmaceutical, healthcare, medical-service, investment and international cooperation activities.
2026
Sinopharm expands international operations across more than 70 countries and regions[13]Sinopharm international expansion reporten.sinopharm.com
Other
Sinopharm described international expansion through exports, vaccine localization, overseas healthcare projects and Belt and Road cooperation, including production collaborations for several vaccine categories.
2025
Sinopharm’s Tongtian Oral Liquid receives Canadian natural-health authorization[14]Sinopharm Tongtian Oral Liquid authorization in Canadaen.sinopharm.com
Product launch · Other
A traditional Chinese medicine product developed by a Sinopharm subsidiary received market authorization in Canada as a Natural Health Product, extending the international reach of the group’s TCM portfolio.
2024
Sinopharm expands procurement partnerships at the seventh China International Import Expo[19]China International Import Expo participationen.sinopharm.com
Campaign · M&A · Other
Sinopharm signed procurement agreements with international medical-device, healthcare and nutrition companies, emphasizing high-end equipment, imported healthcare products and supply-chain cooperation.
2024
Sinopharm signs strategic cooperation framework with the University of Macau[18]University of Macau strategic cooperationen.sinopharm.com
Other
The group pursued cooperation with the University of Macau in life-health research and related scientific and healthcare fields.
2023
Pfizer signs strategic cooperation pact with Sinopharm Group[15]Pfizer-Sinopharm strategic cooperation reportfinance.yahoo.com
Product launch
Pfizer and Sinopharm Group agreed to cooperate on bringing innovative Pfizer medicines to China, with a plan to seek approval for 12 drugs through 2025.
2023
Sinopharm partners with Elekta to expand radiation therapy in China[22]国药集团与医科达合作，扩大中国放射治疗覆盖en.sinopharm.com
Other
Sinopharm and Elekta announced cooperation intended to broaden access to radiation-therapy technologies and related medical services in China.
2021
WHO lists Sinopharm BIBP COVID-19 vaccine for emergency use[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Product launch · Regulation
The World Health Organization granted emergency-use listing to the Sinopharm vaccine produced by Beijing Bio-Institute of Biological Products, allowing countries to accelerate regulatory approval and enabling COVAX procurement.
2021
Sinopharm COVID-19 vaccine enters international deployment[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Product launch · Campaign
Sinopharm's inactivated vaccine became part of international vaccination campaigns and was supplied to multiple countries through bilateral arrangements and multilateral programs.
2021
WHO issues interim policy recommendations for the Sinopharm vaccine[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Regulation · Product generation
Following its emergency-use assessment, WHO published interim policy recommendations for use of the Sinopharm inactivated vaccine, including recommendations concerning age groups and deployment.

Showing the 10 most recent.

Sources23 sources

Cite this profile: Cite the canonical profile. /brand-wiki/国药集团 · Editorial policy · How profiles are compiled

Overview

History

2026
International business described as reaching more than 70 countries and regions
[13]Sinopharm international expansion reporten.sinopharm.com
Sinopharm reported expanding exports, vaccine localization, overseas healthcare projects and Belt and Road cooperation across more than 70 countries and regions.
2025
Tongtian Oral Liquid authorized in Canada
[14]Sinopharm Tongtian Oral Liquid authorization in Canadaen.sinopharm.com
A traditional Chinese medicine product from Sinopharm’s Taiji Group received Canadian authorization as a Natural Health Product.
2024
University of Macau strategic cooperation
[18]University of Macau strategic cooperationen.sinopharm.com
Sinopharm signed a strategic cooperation framework with the University of Macau covering life-health research and related cooperation.
2023
Pfizer cooperation agreement
[15]Pfizer-Sinopharm strategic cooperation reportfinance.yahoo.com
Pfizer and Sinopharm Group agreed to cooperate on regulatory approval and market access for innovative Pfizer medicines in China.
2021
WHO emergency-use listing for Sinopharm BIBP vaccine
[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
The WHO lists the Sinopharm COVID-19 vaccine for emergency use, enabling its inclusion in international procurement and vaccine-sharing programs.
2020
Chinese authorization of Sinopharm COVID-19 vaccines
[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Inactivated COVID-19 vaccines developed by CNBG units receive Chinese authorization and begin wider domestic deployment.
2020
Sinopharm COVID-19 vaccine candidates enter clinical development
[17]Sinopharm COVID-19 vaccine candidates enter clinical developmenten.wikipedia.org
Sinopharm’s Beijing and Wuhan biological-product institutes advanced inactivated COVID-19 vaccine candidates into clinical trials and international cooperation.
2018
Recall, destruction and regulatory rectification of DPT vaccine
[12]Chinese regulator information on Wuhan DPT vaccinexinhuanet.com
Unused doses were recalled and destroyed; the Wuhan subsidiary was fined and required to improve manufacturing controls and equipment maintenance.
2017
Substandard DPT vaccine identified at Wuhan subsidiary
[12]Chinese regulator information on Wuhan DPT vaccinexinhuanet.com
Regulatory sampling identified an ineffective-potency DPT vaccine batch made by Wuhan Institute of Biological Products.
2010
Shanghai Shyndec becomes part of Sinopharm
[16]Shanghai Shyndec becomes part of Sinopharmen.sinopharm.com
Shanghai Shyndec Pharmaceutical was incorporated into Sinopharm in April 2010 and later participated in chemical-pharmaceutical restructuring.

Showing the 10 most recent.

Products and positioning

Inactivated vaccine · 2020
Sinopharm BIBP COVID-19 vaccine
An inactivated SARS-CoV-2 vaccine developed and manufactured by units of China National Biotec Group. It was used in China's domestic vaccination program and supplied internationally. WHO emergency-use listing in 2021 enabled its consideration for international procurement and deployment. An inactivated-virus COVID-19 vaccine developed by Sinopharm’s Beijing Institute of Biological Products under China National Biotec Group. Known as BBIBP-CorV or the BIBP vaccine, it was tested in international Phase III studies and received WHO emergency-use listing on May 7, 2021. Its conventional refrigerated storage requirements supported distribution in countries without extensive ultra-cold-chain infrastructure. A second inactivated-virus COVID-19 vaccine developed by Sinopharm’s Wuhan Institute of Biological Products. The product was developed separately from the Beijing BIBP vaccine and formed part of Sinopharm’s pandemic vaccine portfolio.
Vaccines
Human vaccines
Sinopharm's biological-product businesses develop and manufacture vaccines for infectious diseases and public-health programs. The portfolio is produced through specialized institutes and manufacturing companies rather than through one uniform consumer-facing product line.
Healthcare distribution · 2003
Pharmaceutical distribution services
The group's distribution operations supply prescription medicines, biological products, medical devices, and other healthcare goods to hospitals, pharmacies, clinics, and public-health institutions. This is one of Sinopharm's defining capabilities and is particularly significant in China's institutional healthcare market. Through Sinopharm Group, the company distributes medicines, medical devices, consumables and healthcare products to hospitals, community health institutions, pharmacies and other distributors. The business includes warehousing, delivery, supply-chain management and value-added services.
Biologics
Biological products and blood products
Sinopharm companies manufacture and distribute biological medicines, blood-derived products, diagnostic materials, and related products. These activities are concentrated in specialized biological-product subsidiaries and research institutes.
Medical technology
Medical devices and diagnostics
The group participates in medical-device, diagnostic, laboratory, and healthcare-equipment businesses, complementing its pharmaceutical manufacturing and distribution activities.
Biopharmaceuticals
Vaccines and biological products
Sinopharm’s biological-products portfolio includes preventive vaccines, blood products, immunological products and other biotechnology-based medicines produced through China National Biotec Group and affiliated institutes. These products support national immunization, infectious-disease prevention and broader clinical use.
Pharmaceutical medicines
Chemical pharmaceuticals
The group manufactures and distributes a wide range of chemical medicines, including generic and specialty products. Its chemical-pharmaceutical operations have been supported by industrial restructuring, research institutes, manufacturing subsidiaries and Sinopharm’s large distribution network.
Traditional Chinese medicine
Traditional Chinese medicine portfolio
Sinopharm’s TCM activities include proprietary medicines, oral liquids and herbal preparations produced by subsidiaries such as Taiji Group. Products are marketed in China and, for selected formulations, in international markets including Singapore, Malaysia and Canada.
Medical devices
Medical-device distribution and supply-chain services
Sinopharm distributes diagnostic, surgical, imaging, laboratory, treatment and hospital-support equipment. It also works with international manufacturers to introduce advanced devices and healthcare technologies into the Chinese market.
Retail healthcare
Retail pharmacy and healthcare services
The group’s commercial subsidiaries operate retail pharmacies, professional pharmacy formats, direct-to-patient services, retail clinics and related healthcare platforms. These businesses connect Sinopharm’s wholesale network with consumers and community-based healthcare delivery.

Controversies

2017
Substandard DPT vaccine batch produced by Wuhan Institute of Biological Products
Chinese regulatory sampling found that a DPT vaccine batch produced by Sinopharm’s Wuhan Institute of Biological Products failed potency requirements. Regulators reported that 400,520 doses were affected. The stated cause was a temporary filling-equipment malfunction that made the vaccine suspension uneven. Unused doses were recalled and destroyed, and the subsidiary was fined and required to strengthen equipment maintenance, filling procedures, training and quality controls.
Source
Ineffective DPT vaccine incident (2017)
Source

Marketing campaigns

2025Internationalization of traditional Chinese medicine
Canada · Singapore · Malaysia · Other international markets
Sinopharm promoted selected traditional Chinese medicine formulations through overseas registrations, trade events and local market access initiatives.
Outcome. Tongtian Oral Liquid received Canadian authorization as a Natural Health Product, while other Taiji products had previously obtained market access in Singapore and Malaysia.
Source
2023All for Health, Health for All
China · International markets
Sinopharm has used the “All for Health, Health for All” theme to frame its public-health, pharmaceutical distribution, supply-security, innovation and international cooperation activities.
Outcome. The theme supports the group’s positioning as a national healthcare platform rather than a single-product pharmaceutical manufacturer.
Source
2021International Sinopharm COVID-19 vaccination deployment
China · Asia · Africa · Latin America · Middle East
Following domestic authorization and WHO emergency-use listing, Sinopharm COVID-19 vaccines were supplied through international agreements, donations, and multilateral vaccine-access programs.
Outcome. The campaign expanded the vaccine's international use and made Sinopharm one of the most visible Chinese vaccine suppliers during the pandemic.
Source
2020Global COVID-19 vaccine supply and vaccination cooperation
Asia · Africa · Europe · South America · Middle East
Sinopharm promoted its inactivated COVID-19 vaccines through international clinical trials, government procurement, technology cooperation, local manufacturing discussions and vaccination campaigns. The effort focused particularly on countries where conventional refrigerated distribution was more practical than ultra-cold-chain systems.
Outcome. The BIBP vaccine received WHO emergency-use listing in May 2021 and became one of the Chinese vaccines used in international immunization programs and COVAX-related procurement.
Source
2018China International Import Expo participation
China · International supplier markets
Sinopharm began participating in the China International Import Expo in 2018, using the event to connect Chinese healthcare demand with global pharmaceutical, medical-device, nutrition and health-product suppliers.
Outcome. The expo became an important annual platform for procurement agreements, international partnerships and the introduction of foreign medical technologies into China.
Source

Brand decisions

2024
Expand international procurement and medical-technology partnershipsStrategy
Background
Sinopharm sought to combine its domestic distribution capabilities with international medical technologies and healthcare products.
Action taken
The group used the China International Import Expo and related initiatives to sign procurement agreements and deepen cooperation with global medical-device and healthcare companies.
Aftermath
The strategy reinforced Sinopharm’s position as an importer, distributor, technology partner and healthcare-supply-chain integrator.
Source
2023
Cooperate with Pfizer on innovative medicines in ChinaStrategy
Background
Pfizer sought to broaden access to innovative medicines in China, while Sinopharm possessed extensive regulatory, distribution and commercial infrastructure.
Action taken
Pfizer and Sinopharm Group signed a strategic cooperation agreement covering applications for 12 innovative drugs through 2025.
Aftermath
The agreement illustrated Sinopharm’s role as a local market-access and distribution partner for multinational pharmaceutical companies.
Source
2021
Pursuit of international vaccine supplyStrategy
Background
Global vaccine shortages and unequal access created demand for additional suppliers beyond the first Western-developed vaccines.
Action taken
Sinopharm supplied vaccine doses to overseas markets and participated in international access and procurement arrangements after WHO emergency-use listing.
Aftermath
The group increased its international healthcare visibility and strengthened its role in China's outward-facing public-health and pharmaceutical activities.
Source
2020
Emergency development and deployment of an inactivated COVID-19 vaccineProduct launch
Background
The COVID-19 pandemic created urgent demand for vaccines and expanded the strategic importance of domestic vaccine manufacturing.
Action taken
CNBG units developed, manufactured, and supplied an inactivated SARS-CoV-2 vaccine for domestic use, followed by international distribution.
Aftermath
The vaccine became a major international product and later received WHO emergency-use listing, while its evidence base and transparency were subject to international discussion.
Source
2020
Develop and commercialize inactivated COVID-19 vaccinesProduct launch
Background
The COVID-19 pandemic created urgent demand for vaccines that could be manufactured at scale and distributed through conventional refrigerated supply chains.
Action taken
Sinopharm’s Beijing and Wuhan biological-product institutes advanced separate inactivated-virus vaccine candidates through clinical development, regulatory review and international partnerships.
Aftermath
The BIBP vaccine received WHO emergency-use listing in May 2021 and became a major product in Sinopharm’s international profile.
Source
2009
Merge with China National Biotec GroupM&A
Background
Sinopharm sought to strengthen its biological-products and public-health manufacturing capabilities.
Action taken
China National Biotec Group was merged into Sinopharm.
Aftermath
The merger expanded the group’s vaccine, blood-product and biotechnology platform and supported later COVID-19 vaccine development.
Source
1998
Create a national pharmaceutical holding platformStrategy
Background
China had multiple large state-owned pharmaceutical, foreign-trade and medical-device enterprises operating across related parts of the healthcare system.
Action taken
The government established China National Pharmaceutical Group Corporation as a holding company consolidating four major predecessor organizations.
Aftermath
The structure gave Sinopharm a broad base in manufacturing, foreign trade, medical devices and pharmaceutical supply, and later enabled further sector consolidation.
Source

Recent events

2026
Sinopharm chairman attends UK-China Business Council meeting[21]国药集团董事长出席英中贸易协会会议en.sinopharm.com
Leadership change · Other
Chairman Bai Zhongquan represented Sinopharm at a UK-China business meeting and highlighted the group’s broad pharmaceutical, healthcare, medical-service, investment and international cooperation activities.
2026
Sinopharm expands international operations across more than 70 countries and regions[13]Sinopharm international expansion reporten.sinopharm.com
Other
Sinopharm described international expansion through exports, vaccine localization, overseas healthcare projects and Belt and Road cooperation, including production collaborations for several vaccine categories.
2025
Sinopharm’s Tongtian Oral Liquid receives Canadian natural-health authorization[14]Sinopharm Tongtian Oral Liquid authorization in Canadaen.sinopharm.com
Product launch · Other
A traditional Chinese medicine product developed by a Sinopharm subsidiary received market authorization in Canada as a Natural Health Product, extending the international reach of the group’s TCM portfolio.
2024
Sinopharm expands procurement partnerships at the seventh China International Import Expo[19]China International Import Expo participationen.sinopharm.com
Campaign · M&A · Other
Sinopharm signed procurement agreements with international medical-device, healthcare and nutrition companies, emphasizing high-end equipment, imported healthcare products and supply-chain cooperation.
2024
Sinopharm signs strategic cooperation framework with the University of Macau[18]University of Macau strategic cooperationen.sinopharm.com
Other
The group pursued cooperation with the University of Macau in life-health research and related scientific and healthcare fields.
2023
Pfizer signs strategic cooperation pact with Sinopharm Group[15]Pfizer-Sinopharm strategic cooperation reportfinance.yahoo.com
Product launch
Pfizer and Sinopharm Group agreed to cooperate on bringing innovative Pfizer medicines to China, with a plan to seek approval for 12 drugs through 2025.
2023
Sinopharm partners with Elekta to expand radiation therapy in China[22]国药集团与医科达合作，扩大中国放射治疗覆盖en.sinopharm.com
Other
Sinopharm and Elekta announced cooperation intended to broaden access to radiation-therapy technologies and related medical services in China.
2021
WHO lists Sinopharm BIBP COVID-19 vaccine for emergency use[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Product launch · Regulation
The World Health Organization granted emergency-use listing to the Sinopharm vaccine produced by Beijing Bio-Institute of Biological Products, allowing countries to accelerate regulatory approval and enabling COVAX procurement.
2021
Sinopharm COVID-19 vaccine enters international deployment[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Product launch · Campaign
Sinopharm's inactivated vaccine became part of international vaccination campaigns and was supplied to multiple countries through bilateral arrangements and multilateral programs.
2021
WHO issues interim policy recommendations for the Sinopharm vaccine[3]WHO lists additional COVID-19 vaccine for emergency usewho.int
Regulation · Product generation
Following its emergency-use assessment, WHO published interim policy recommendations for use of the Sinopharm inactivated vaccine, including recommendations concerning age groups and deployment.

Showing the 10 most recent.

Overview

History

Products and positioning

Controversies

Marketing campaigns

Brand decisions

Recent events

Related entries

Sources23 sources

Overview

History

Products and positioning

Controversies

Marketing campaigns

Brand decisions

Recent events

Related entries

Sources23 sources